The MSCI series index is a stock index compiled by Morgan Stanley Capital International. It is one of the most influential stock indexes in the world and one of the benchmark indexes most used by international investors. It is adjusted quarterly and semi-annually to add or remove components to maintain the authority of the index. On May 13, 2022, MSCI announced the results of the semi-annual review of the MSCI GLOBAL SMALL CAP INDEXES, Kintor Pharma was included in MSCI China Index. 

Previously, Kintor Pharma was added to the FTSE Index in 2020, the Hang Seng Composite Index and Hong Kong Stock Connect Program in 2021.

Dr. Tong Youzhi, the founder, Chairman, and CEO of Kintor Pharma commented, "We are excited to be included in the MSCI China Index as it reflects the recognition of and confidence in our company's business and development prospects from the international capital markets. Kintor expects that the inclusion in the MSCI China Index will facilitate further expansion of the our investor base and enhance the liquidity of the company's stock– both of which will have a positive impact on our development. Kintor Pharma will continue to advance its progress in research and development, clinical operations, and our commercialization efforts to deliver medicines that advance human health."